Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
February 6, 2020 4:14 PM EST
Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Companys Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.
As we position Myriad for its next phase of growth and... More
February 6, 2020 4:13 PM EST
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.23, $0.08 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $209.81 million.
GUIDANCE:
Myriad Genetics sees Q3 2020 EPS of $0.02, versus the consensus of $0.30. Myriad... More
